Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RECQL5
REST API REST API
Homo sapiens
RECQL5 is differentially expressed in 266 experiments: 153 organism parts: bone marrow, lung, ... (151 more);, 217 disease states: normal, breast carcinoma, ... (215 more);, 88 cell types 321 cell lines 36 compound treatments and 81 other conditions.
Synonyms RecQ5, FLJ90603
Orthologs RECQL5 (Gallus gallus)   Recql5 (Mus musculus)   SGS1 (Saccharomyces cerevisiae)   Recql5 (Rattus norvegicus)   RECQL5 (Bos taurus)   RECQL5 (Danio rerio)   ENSCING00000013281 (Ciona intestinalis)   RecQ5 (Drosophila melanogaster)   RECQL5 (Xenopus laevis)   XM_540436.2 (Canis familiaris)   ENSCAFG00000025513 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, DNA repair, cytoplasm, ATP-dependent helicase activity, nucleic acid binding, ATP binding, nucleus, DNA recombination, nucleotide binding, DNA helicase activity, hydrolase activity, nucleoplasm, nucleolus, helicase activity, nuclear membrane, DNA metabolic process
InterPro Term DNA/RNA_helicase_DEAD/DEAH_N, RecQ_helicase-like_5, Helicase_C, DNA_helicase_ATP-dep_RecQ, DEAD-like_helicase, Helicase/UvrB_dom
UniProt Accession Q8WYH5, O94762, B7Z8Y7, Q9BW80, Q9BSD6
Search EB-eye ENSG00000108469
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (35 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
PC3
2
E-GEOD-5258, E-MEXP-2034
primary culture
2
E-GEOD-2450, E-GEOD-1657
BT474
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
315 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (47 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-TABM-145, E-AFMX-5
testis - germ cell
2
E-AFMX-5, E-TABM-145
fibroblast
1
2
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-MEXP-2034
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
native fetal RPE
1
E-GEOD-18811
82 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, ... (54 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-20602, E-GEOD-21912, E-GEOD-20295, E-GEOD-16363
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
neuroblastoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
211 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (21 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-GEOD-412, E-TABM-782, E-MEXP-1958, E-GEOD-7307, ... (7 experiments)
lipopolysaccharide
1
2
E-MEXP-1958, E-GEOD-3720, E-TABM-868
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
NaOH
1
1
E-MEXP-2590
phoshate buffered saline
1
E-GEOD-3720
selenium
1
E-MEXP-1327
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-22278, E-GEOD-10315, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-3720, E-GEOD-1926, E-GEOD-19136, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-5820 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-15811

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.443 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM